// App-Quantinova.ai

: Phase II Study of Blinatumomab in Patients with B-Cell Lineage Acute Lymphocytic Leukemia with Positive Minimal/Measurable Residual Disease

Researchers

Presenter

  • Iman Aboudalle

Principal Investigators

  • Hagop M. Kantarjian

  • Nicholas J Short

  • Maria Khouri

  • Koichi Takahashi

  • Maro N. Ohanian

  • Gautam Borthakur

  • Marina Y. Konopleva

  • Naval G. Daver

  • Zeev E. Estrov

  • Yesid Alvarado

  • Nitin Jain

  • Farhad Ravandi

  • Guillermo Garcia-Manero

  • Michelle Velasquez

  • Patrice Nasnas

  • Susan M. O'Brien

  • Elias J. Jabbour

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Radiology, MD Anderson Cancer Center, Houston, TX

  • Department of Radiology, MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Chao Family Comprehensive Cancer Center, University of California, Orange, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • Ph chromosome

Drug/Treatment

  • Blinatumomab

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved